|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||1.5180 - 1.5380|
|52-week range||1.5180 - 1.5380|
|Beta (5Y monthly)||1.16|
|PE ratio (TTM)||N/A|
|Earnings date||11 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.